BioInvent International
8.12.2021 08:21:38 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV)
- BioInvent's pipeline expanding to four drug candidates in five clinical trials
Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial Application (CTA) for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
BI-1607 targets FcyRIIB but is modified in its Fc region to alter its affinity for Fc receptors. By selectively blocking FcyRIIB, BI-1607 enhances the activity of other therapeutic monoclonal antibodies, whose mechanism-of-action involves depletion of tumors or immune suppressive cells. Understanding the biology of FcR/Fc interactions was essential for generating BI-1607, which has a clearly differentiated profile from BioInvent's lead drug candidate BI-1206.
BioInvent intends to explore the activity of BI-1607 in advanced solid tumors and antibody combinations supported by strong preclinical data.
"We are pleased to have completed this step in the development. BI-1607 is a very promising approach given its ability to enhance anti-cancer immunity and approval of the CTA will expand the BioInvent pipeline to four drug candidates in five clinical trials, further underlining the productivity of our technology platform," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. In addition to BI-1607, the company has three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/676499/BioInvent-has-Submitted-a-CTA-for-a-Phase-12a-trial-of-BI-1607-a-Novel-anti-FcyRIIB-Antibody-for-the-Treatment-of-Patients-with-Solid-Tumors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X to Present at the Small Cap Growth Virtual Investor Conference June 4th1.6.2026 15:30:00 CEST | Press release
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com CALGARY, AB / ACCESS Newswire / June 1, 2026 / Karbon-X Corp. (OTCQB:KARX), based in Calgary, Alberta focused on global carbon markets and climate infrastructure solutions, today announced that Chad Clovis, Chief Executive Officer will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on June 4, 2026 DATE: June 4th TIME: 10:00 AM ET REGISTER HERE Available for 1x1 meetings: June 5th-9th Schedule 1x1 Meetings here. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive
Resin Solutions LLC Introduces "Stratix(TM)" Brand Architecture for Products Serving the Aerospace and Defense Applications1.6.2026 15:00:00 CEST | Press release
EXTON, PA / ACCESS Newswire / June 1, 2026 / Resin Solutions LLC, a leading provider of advanced material solutions, today announced the launch of Stratix™, a new brand identity reflecting the company's deepened strategic focus on the Aerospace and Defense sector. This new designation underscores the company's long-term commitment to supporting the unique and demanding requirements of aerospace and defense customers. By clearly bringing both its existing and in-development aerospace and defense products under the Stratix™ brand name, Resin Solutions aims enhance customer confidence, streamline product selection, and further strengthen its partnerships within the sector. The Stratix™ brand trademark will be applied to a growing portfolio of materials engineered to meet the rigorous performance, quality, and reliability expectations critical to aerospace and defense applications. Among the first products to carry the designation are Resin Solutions' flagship and highly-specified aerospac
AccessPay Appoints Johan Jardevall as CEO to Lead Next Phase of Growth1.6.2026 10:00:00 CEST | Press release
-- MANCHESTER, GB / ACCESS Newswire / June 1, 2026 / AccessPay, the leading bank integration provider, today announced the appointment of Johan Jardevall as Chief Executive Officer. Johan succeeds Anish Kapoor, who will become Chairman. Anish is stepping down after more than a decade leading the company through a significant period of growth, technology transformation, and platform development. Johan brings more than 25 years of experience leading and scaling enterprise software and SaaS businesses across Europe and the UK. He has held several senior executive and CEO positions within high-growth technology companies, with expertise spanning operational leadership, customer delivery, strategic growth, and product commercialisation. Most recently, Johan served as CEO of Person Centred Software, where he led the company through a significant phase of operational and commercial growth. The leadership transition follows AccessPay's recent strategic majority investment from Accel-KKR and ma
POLARIS Laboratories Joins the Dow Coolant Care Network as Testing Provider for DOWFROST Heat Transfer Fluids28.5.2026 15:00:00 CEST | Press release
INDIANAPOLIS, IN / ACCESS Newswire / May 28, 2026 / POLARIS Laboratories® today announced Dow has selected POLARIS Laboratories® as a testing provider for DOWFROST™ LC and HD Heat Transfer Fluids used in advanced cooling systems. This collaboration reinforces Dow's commitment to helping customers move beyond reactive maintenance practices toward proactive, data-driven fluid management. DOWFROST™ Heat Transfer Fluids are engineered to support next-generation data center cooling, including direct-to-chip liquid cooling architectures. Formulated with high-purity propylene glycol and advanced inhibitor technology, these fluids enable efficient heat removal, corrosion protection, and long-term operational stability in high-performance computing environments. To meet thermal demands from Artificial Intelligence (AI) and high-density computing, monitoring liquid cooling fluid is critical to protect uptime, maintain performance and reduce operational risk. The Dow Coolant Care Network integrat
Caldwell Strengthens Financial Services and Fintech Capabilities with Addition of Alex Langridge in London28.5.2026 10:30:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / May 28, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Alex Langridge as a Partner in the firm's Financial Services Practice. Based in London, Langridge advises clients across financial services and fintech on senior executive and board appointments, succession planning, organizational design, and transformational leadership hiring. Based in London, Alex Langridge joins Caldwell's Financial Services Practice, bringing deep expertise across banking, fintech, insurance, and transformational leadership advisory. Langridge brings more than 20 years of executive search and leadership advisory experience, partnering with banks, insurers, fintechs, and private equity- and venture-backed businesses across the UK and EMEA. He is particularly known for placing P&L, operations, commercial, product, technology, and digital leaders into high-impact transformational roles, as well as for helping cli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom